Navigation Links
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
Date:5/18/2012

>

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015  Medimetriks Pharmaceuticals, ... the second Phase III clinical study for Ozenoxacin, ... impetigo.  Medimetriks owns the exclusive U.S. rights to ... trial, conducted at 44 centers with an emphasis ... patients aged 2 months and older with a ...
(Date:7/30/2015)... Global ENT (Ear, Nose, ... USD 23.01 million in 2022, according to a new ... geriatric population, increasing prevalence of ear, nose, and throat ... among target customer base are expected serve this market ... According to estimates published by the WHO, 15% of ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
... Findings Reinforce March of Dimes Message: Start Taking a ... 11 Women who take folic acid supplements for ... cut their risk of having a premature baby by ... online journal, PLOS Medicine.The study links pre-conceptional folate supplementation ...
... Announces Positive Top Line Results of its Clinical Study ... Mass., May 11 Logical Therapeutics, Inc (Logical), a ... treat diseases associated with inflammation, today announced that Peter ... has been elected to the Company,s Board of Directors. ...
Cached Medicine Technology:Taking Folic Acid for a Year Before Pregnancy May Reduce Risk of Preterm Birth 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 2Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 3Logical Therapeutics Appoints Peter A. Lankau as CEO and Director 4
(Date:7/30/2015)... ... 2015 , ... The New Jersey Innovation Institute (NJII), acting ... Health, has received a $2.9 million grant from the Office of the National ... and Human Services (HHS). NJII will help the Department of Health ensure the ...
(Date:7/30/2015)... ... July 30, 2015 , ... InventHelp, a leading inventor service ... personal-care device that makes it easy to apply lotion or medication to a hard-to-reach ... assistance when applying lotion or medication to the back, and provides thorough coverage. The ...
(Date:7/30/2015)... ORLEANS (PRWEB) , ... July 30, 2015 , ... Author ... and take charge of their health in his new self-help book, “ Consciously Healing ... Llanos’ new book promotes a simple message: “If we take responsibility for ourselves, we ...
(Date:7/30/2015)... ... , ... Summer is the dry eye season, especially in parts of the ... and hot 2015 summer season and the dry eye rate in the hot spots ... the 2015 summer season and identify the primary dry eye hot spots on her ...
(Date:7/30/2015)... ... July 30, 2015 , ... HEALTHCAREfirst , the leading ... announced today that it is hosting a free webinar detailing the 2016 proposed rule ... HEALTHCAREfirst Consultant and former Vice President of Regulatory Affairs for the National Association for ...
Breaking Medicine News(10 mins):Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2
... , NEW YORK, Dec. 10 SIRIUS ... Doctor Radio Reports: Kids and Video Games - What ... by journalist Perri Peltz on which she and a panel of experts ... effects they have on children. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO ) , ...
... , SALEM, Ore., Dec. 10 West Coast Bank,s ... Bears for children hospitalized at the Salem Hospital Pediatric Wing and ... Bears at the branch, 5686 Commercial St. SE, Suite 110 on ... BSN CPN, Nurse Manager of Pediatrics at Salem Hospital said, "The ...
... of alcoholic beverages (at least three to four drinks per ... a 30 percent increased risk of breast cancer recurrence, according ... may be most susceptible to the effects of alcohol on ... of this study will be presented December 9-13 at the ...
... to die or be disabled by midlife, study finds, , THURSDAY, ... a man,s risk of dying or becoming disabled by the time ... findings are from a study that began following 411 South London ... those who at age 10 displayed antisocial behavior (such as skipping ...
... ... leader in Sales and Operations Planning (S&OP) solutions, announced a program ... JDA The Steelwedge "i2 Exchange Program" address i2 customers that ... recently announced merger between i2 and JDA (formerly Manugistics), or are ...
... , RANCHO CORDOVA, Calif., Dec. 10 ThermoGenesis Corp. (Nasdaq: ... processing and storing adult stem cells, said today that Craig ... industry experience, has been named to the Company,s board of ... to six. , Moore is currently associated with several public ...
Cached Medicine News:Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: Kids and Video Games - What You Should Know Before You Buy' 4Health News:Alcohol consumption may increase breast cancer recurrence risk 2Health News:Bad Behavior as a Kid Linked to Early Death in Men 2Health News:Leading Sales and Operations Planning (S&OP) Provider Steelwedge Announces i2 Exchange Program 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 2Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 3Health News:ThermoGenesis Corp. Names Healthcare Industry Executive Craig Moore to Board of Directors 4
Inquire...
Sebia's Hb AFSC Control provides excellent resolution of normal hemoglobins A & F and abnormal hemoglobins S & C. The control is designed for use with Sebia's Hydragel Hemoglobin and Hydragel Acid He...
... and Hypergamma Controls are designed ... agarose gels or Sebia's ... unique control manufacturing process preserves ... other serum components, presenting a ...
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field....
Medicine Products: